Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Revenio: Not a one-trick pony

REG1VExtensive research15.06.2021, 07.11
Juha Kinnunen, Mikael Rautanen
Discuss
Download report (PDF)

Revenio is known as the global beacon of tonometers but these days the company is a noteworthy challenger in more extensive ophthalmic health technology. Imaging tools (previous CenterVue) play an increasing role in future growth and HOME products, as well as software business offer longer term growth promises. Business is growing very profitably, the market has sound growth drivers, and the products have strong competitive advantages. In addition, the company has an excellent track record of its ability to create value with investments in product development, structural reorganization, and new long-term growth templates

Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand. In 2023, the Group’s net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Read more on company page

Key Estimate Figures08.06.2021

202021e22e
Revenue61.179.3102.5
growth-%23.4 %29.9 %29.2 %
EBIT (adj.)19.227.237.1
EBIT-% (adj.)31.4 %34.3 %36.2 %
EPS (adj.)0.490.690.92
Dividend0.270.330.46
Dividend %0.6 %3.2 %4.4 %
P/E (adj.)86.615.111.3
EV/EBITDA61.511.68.0

Forum discussions

Nyt meni merkitseminen läpi kun rahat tuli T+2 pv ajassa OSTin hoitotilille. Se ei siis riitä, että OSTilta myy osakkeita ja saa varat käytett...
9/30/2026, 7:35 AM
by palse
7
Jahas, taisi Caravelle saada eilen hankittua haluamansa määrän merkkareita ja nyt niiden kurssi sukeltaa.
9/30/2026, 7:11 AM
by Kryptoniitti
3
I just realized that Revenio’s rights issue presentation webcast was today. A couple of approvals and registration are required before you can...
9/29/2026, 5:44 PM
by NukkeNukuttaja
4
“We used to have a very highly profitable company → well, now it’s a lot less profitable company Return on capital was high → well, now it’s...
9/29/2026, 3:10 PM
by Optis
25
Yesterday’s arbitrage of about €0.20/share melted away today. According to Nordnet’s broker statistics, all the big net buyers today were American...
9/29/2026, 2:09 PM
by Juurikki
5
I think so too, and yes, subscription rights can only be bought for a traditional osakeopstitiili (AOT) [share savings account]. Let’s see if...
9/29/2026, 10:45 AM
by palse
1
Of course, you can subscribe to new issues with an equity savings account (OST), but you can’t buy subscription rights (merkkari) because you...
9/29/2026, 10:22 AM
by FanTom
5